ReviewNeuro-oncology2013
Which drug or drug delivery system can change clinical practice for brain tumor therapy?
Review in Neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Metal nanoparticles in neuroinflammation: impact on microglial dynamics and CNS function.RSC advances · 2025Review
- A new nano approach to prevent tumor growth in the local treatment of glioblastoma: Temozolomide and rutin-loaded hybrid layered composite nanofiber.Asian journal of pharmaceutical sciences · 2024Article
- Lipid-core nanocapsules containing simvastatin do not affect the biochemical and hematological indicators of toxicity in rats.Toxicology research · 2024Article
- Rational Design of Pectin-Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy.Biomedicines · 2024Article
- Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model.Brain sciences · 2023Article
- Improved Activity of Herbal Medicines through Nanotechnology.Nanomaterials (Basel, Switzerland) · 2022Review
- Microglia-targeting nanotherapeutics for neurodegenerative diseases.APL bioengineering · 2020Article
- The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.Frontiers in neuroscience · 2020Review
- Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.Pharmaceutics · 2019Article
- Article
- Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells.Journal of cellular and molecular medicine · 2018Article
- Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Theranostics · 2018Article
- Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma.Journal of nanomedicine & nanotechnology · 2017Article
- Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.Scientific reports · 2017Article
- Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers.Biomaterials · 2015Article
- Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis.Oncotarget · 2015Article
- Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.British journal of cancer · 2015Article
- DIPG in Children - What Can We Learn from the Past?Frontiers in oncology · 2015Review
- Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells.OncoTargets and therapy · 2015Article
- Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis and treatment outcome for primary brain tumors have remained unchanged despite advances in anticancer drug discovery and development. In clinical trials, the majority of promising experimental agents for brain tumors have had limited impact on survival or time to recurrence. These disappointing results are partially explained by the inadequacy of effective drug delivery to the CNS. The impediments posed by the various specialized physiological barriers and active efflux mechanisms lead to drug failure because of inability to reach the desired target at a sufficient concentration. This perspective reviews the leading strategies that aim to improve drug delivery to brain tumors and their likelihood to change clinical practice. The English literature was searched for defined search items. Strategies that use systemic delivery and those that use local delivery are critically reviewed. In addition, challenges posed for drug delivery by combined treatment with anti-angiogenic therapy are outlined. To impact clinical practice and to achieve more than just a limited local control, new drugs and delivery systems must adhere to basic clinical expectations. These include, in addition to an antitumor effect, a verified favorable adverse effects profile, easy introduction into clinical practice, feasibility of repeated or continuous administration, and compatibility of the drug or delivery system with any tumor size and brain location.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.